89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors

Inclusion

• Patients diagnosed with locally advanced or metastatic solid tumors by histopathology or cytology;
• Patients with diabetes who have a fasting blood glucose greater than 10 mmol/L;
• Patients with allergies or allergies to any component of the imaging agent or antibody;
• Received anti-tumor therapy (including but not limited to chemotherapy, radiotherapy, biological therapy) within 4 weeks prior to first dose;
• Patients with symptomatic ascites, pleural effusion, or hydropericardium;
• Patients with systemic or locally severe infections (CTCAE ≥ 2);
• Symptomatic congestive heart failure (NYHA class II-IV) or symptomatic or poorly controlled arrhythmia;
• Patients are regular users (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol);
• HIV antibody positive, active hepatitis B/C, and TB positive;
• Pregnant or lactating women, or planning to become pregnant or have children during this trial.
• Inclusion Criteria (main):
• Patents have not recovered to CTCAE grade 0 or 1 from the adverse events due to cancer therapeutics administered;
• Patients have significant QT/QTC interval prolongation during the screening period;
• Currently or within the first 28 days before the first dose to participate in another therapeutic clinical trial. If participating in a non-interventional clinical trial, it is not be excluded.
• Intolerance of intravenous administration, as well as difficulties in venous blood collection (If having the medical history of fainting during acupuncture, and blood phobia);
• Previously received CD137 agonist or immune checkpoint blocking therapy;
• Patients who cannot undergo PET/CT imaging;
• Patients with biopsy-proven PD-L1 positive;
• ECOG score ≤ 0\~1; Life expectancy of at least 3 months;

Exclusion

Exclusion criteria not yet provided.